Home » Market News » DirectorsTalk Highlights » CHIMagents to support Hvivo with design, manufacturing and testing of its challenge agents
Open Orphan PLC

CHIMagents to support Hvivo with design, manufacturing and testing of its challenge agents

Dublin-listed Open Orphan has signed an option to buy CHIMagents for a nominal sum.

CHIMagents was recently established to assist in the design, manufacture and testing of challenge agents which are used in clinical trials.

CHIMagent’s CEO and co-founder Adrian Wildfire has more than 20 years of industry experience and will join Open Orphan subsidiary Hvivo as a director of scientific and business strategy.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.